Roche To Acquire 89bio In $3.5B Deal Enhancing Pipeline In Cardiovascular, Renal, And Metabolic Diseases With FGF21 Analog

Author: Benzinga Newsdesk | September 18, 2025 02:42am

• 89bio's pegozafermin allows for a potentially best-in-disease treatment for moderate to severe Metabolic Dysfunction-Associated Steatohepatitis (MASH), one of the most prevalent comorbidities of obesity
• Acquisition supports Roche's strategy as it enhances the company's portfolio in cardiovascular, renal, and metabolic diseases (CVRM) and offers optionality for future combination development
• Roche to acquire 89bio for US$14.50 per share in cash at closing, representing a total equity value of approximately US$2.4 billion. Stockholders would also receive a non-tradeable contingent value right (CVR) for up to an aggregate of US$6.00 per share in cash, representing a total deal value of up to approximately US$3.5 billion

Posted In: ETNB RHHBF RHHBY